TWI805629B - 用於治療發炎性病症之新穎化合物及其醫藥組合物 - Google Patents

用於治療發炎性病症之新穎化合物及其醫藥組合物 Download PDF

Info

Publication number
TWI805629B
TWI805629B TW107136998A TW107136998A TWI805629B TW I805629 B TWI805629 B TW I805629B TW 107136998 A TW107136998 A TW 107136998A TW 107136998 A TW107136998 A TW 107136998A TW I805629 B TWI805629 B TW I805629B
Authority
TW
Taiwan
Prior art keywords
methyl
pyridin
imidazo
amino
pyridine
Prior art date
Application number
TW107136998A
Other languages
English (en)
Chinese (zh)
Other versions
TW201918483A (zh
Inventor
朱維尼 皮卓 都尼蘇 寇提
賽巴斯汀 勞倫 賽維亞 馬堤那
皮爾特 伊莎貝爾 羅傑 克拉斯
奧斯卡 曼默爾堤
德 普拉斯 史蒂芬 艾蜜勒 凡
雷內 亞歷山大 蓋倫
大衛 阿曼提尼
瑞吉納德 克里斯多夫 薩維爾 布萊斯
丹尼斯 毛利斯 阿努特
拉摩斯 米立安 洛佩茲
Original Assignee
比利時商葛萊伯格有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 比利時商葛萊伯格有限公司 filed Critical 比利時商葛萊伯格有限公司
Publication of TW201918483A publication Critical patent/TW201918483A/zh
Application granted granted Critical
Publication of TWI805629B publication Critical patent/TWI805629B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW107136998A 2017-10-20 2018-10-19 用於治療發炎性病症之新穎化合物及其醫藥組合物 TWI805629B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1717260.2A GB201717260D0 (en) 2017-10-20 2017-10-20 Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders
GB1717260.2 2017-10-20
??1717260.2 2017-10-20

Publications (2)

Publication Number Publication Date
TW201918483A TW201918483A (zh) 2019-05-16
TWI805629B true TWI805629B (zh) 2023-06-21

Family

ID=60481889

Family Applications (2)

Application Number Title Priority Date Filing Date
TW107136998A TWI805629B (zh) 2017-10-20 2018-10-19 用於治療發炎性病症之新穎化合物及其醫藥組合物
TW112121026A TWI866258B (zh) 2017-10-20 2018-10-19 用於治療發炎性病症之新穎化合物及其醫藥組合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW112121026A TWI866258B (zh) 2017-10-20 2018-10-19 用於治療發炎性病症之新穎化合物及其醫藥組合物

Country Status (30)

Country Link
US (3) US11564923B2 (cg-RX-API-DMAC7.html)
EP (2) EP4265254A3 (cg-RX-API-DMAC7.html)
JP (2) JP7292271B2 (cg-RX-API-DMAC7.html)
KR (1) KR102757425B1 (cg-RX-API-DMAC7.html)
CN (2) CN117534670A (cg-RX-API-DMAC7.html)
AR (1) AR113784A1 (cg-RX-API-DMAC7.html)
AU (2) AU2018350592B2 (cg-RX-API-DMAC7.html)
CA (1) CA3079449A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020005200A2 (cg-RX-API-DMAC7.html)
DK (1) DK3697784T5 (cg-RX-API-DMAC7.html)
ES (1) ES2967432T3 (cg-RX-API-DMAC7.html)
FI (1) FI3697784T5 (cg-RX-API-DMAC7.html)
GB (1) GB201717260D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20231315T1 (cg-RX-API-DMAC7.html)
HU (1) HUE063998T2 (cg-RX-API-DMAC7.html)
IL (2) IL273943B2 (cg-RX-API-DMAC7.html)
LT (1) LT3697784T (cg-RX-API-DMAC7.html)
MA (1) MA50391B1 (cg-RX-API-DMAC7.html)
MX (1) MX2020003863A (cg-RX-API-DMAC7.html)
MY (1) MY205443A (cg-RX-API-DMAC7.html)
PH (1) PH12020550230A1 (cg-RX-API-DMAC7.html)
PL (1) PL3697784T3 (cg-RX-API-DMAC7.html)
PT (1) PT3697784T (cg-RX-API-DMAC7.html)
RS (1) RS64800B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202003516TA (cg-RX-API-DMAC7.html)
SI (1) SI3697784T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300377T1 (cg-RX-API-DMAC7.html)
TW (2) TWI805629B (cg-RX-API-DMAC7.html)
WO (1) WO2019076716A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202002166B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201717260D0 (en) * 2017-10-20 2017-12-06 Galapagos Nv Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders
EP3976612A4 (en) * 2019-05-28 2023-04-26 Mankind Pharma Ltd NEW COMPOUNDS FOR INHIBITION OF JANUS KINASE 1
JP2023503343A (ja) 2019-11-26 2023-01-27 プラクシス プレシジョン メディシンズ, インコーポレイテッド イオンチャネルモジュレーター
US12668594B2 (en) 2020-12-23 2026-06-30 Sudo Biosciences Limited TYK2 inhibitors and uses thereof
KR20230159421A (ko) 2021-02-19 2023-11-21 수도 바이오사이언시즈 리미티드 Tyk2 억제제 및 이의 용도
IL305119A (en) 2021-02-19 2023-10-01 Sudo Biosciences Ltd Tyk2 inhibitors and uses thereof
TW202302583A (zh) 2021-02-19 2023-01-16 英商蘇多生物科學有限公司 Tyk2抑制劑及其用途
MX2024000517A (es) 2021-07-12 2024-01-31 Galapagos Nv Tratamiento de enfermedades inflamatorias.
TW202339749A (zh) 2021-12-16 2023-10-16 大陸商凌科藥業有限公司 Tyk2抑制劑及其組合物和方法
WO2023161327A1 (en) * 2022-02-24 2023-08-31 Galapagos Nv Compound for use in and methods of treatment of inflammatory diseases
WO2023161326A1 (en) 2022-02-24 2023-08-31 Galapagos Nv Compound for use in and methods of treatment of inflammatory diseases
JP7882100B2 (ja) * 2022-12-07 2026-06-30 富士通株式会社 情報処理プログラム、情報処理方法および情報処理装置
EP4652166A1 (en) 2023-01-18 2025-11-26 Galapagos N.V. Pharmaceutical compositions and solid forms of compound 1 with fumarate for the treatment of inflammatory disorders
CN120584114A (zh) 2023-01-19 2025-09-02 加拉帕戈斯股份有限公司 用于治疗过敏性疾病、炎症性疾病、代谢性疾病、自身炎症性疾病、自身免疫性疾病和增生性疾病的咪唑并[4,5-b]吡啶衍生物
WO2026098666A1 (zh) * 2024-11-11 2026-05-15 杭州领业医药科技有限公司 一种tyk2抑制剂的共晶及其制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013116291A1 (en) * 2012-01-30 2013-08-08 Cephalon, Inc. Imidazo [4, 5 - b] pyridine derivatives as alk and jak modulators for the treatment of proliferative disorders
WO2015110378A1 (en) * 2014-01-23 2015-07-30 Galapagos Nv Benzimidazole derivatives and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102127078A (zh) 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
WO2017012647A1 (en) * 2015-07-20 2017-01-26 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
AR105400A1 (es) 2015-08-04 2017-09-27 Lilly Co Eli Inhibidores de jak1
CN110300590A (zh) 2016-10-21 2019-10-01 林伯士拉克许米公司 Tyk2抑制剂及其用途
GB201717260D0 (en) * 2017-10-20 2017-12-06 Galapagos Nv Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013116291A1 (en) * 2012-01-30 2013-08-08 Cephalon, Inc. Imidazo [4, 5 - b] pyridine derivatives as alk and jak modulators for the treatment of proliferative disorders
WO2015110378A1 (en) * 2014-01-23 2015-07-30 Galapagos Nv Benzimidazole derivatives and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
US12472181B2 (en) 2025-11-18
SG11202003516TA (en) 2020-05-28
GB201717260D0 (en) 2017-12-06
KR102757425B1 (ko) 2025-01-20
PT3697784T (pt) 2024-01-09
RS64800B1 (sr) 2023-11-30
IL302615B1 (en) 2024-06-01
EP4265254A3 (en) 2024-03-13
AU2023201522A1 (en) 2023-04-13
LT3697784T (lt) 2023-10-25
CN117534670A (zh) 2024-02-09
RU2020116376A (ru) 2021-11-22
IL302615A (en) 2023-07-01
FI3697784T5 (fi) 2024-01-12
IL273943A (en) 2020-05-31
AR113784A1 (es) 2020-06-10
JP7292271B2 (ja) 2023-06-16
SMT202300377T1 (it) 2024-01-10
MY205443A (en) 2024-10-22
EP3697784B1 (en) 2023-10-04
SI3697784T1 (sl) 2023-11-30
CN111225916B (zh) 2023-11-03
IL302615B2 (en) 2024-10-01
CN111225916A (zh) 2020-06-02
MA50391B1 (fr) 2023-11-30
KR20200074178A (ko) 2020-06-24
JP2020537672A (ja) 2020-12-24
WO2019076716A1 (en) 2019-04-25
CA3079449A1 (en) 2019-04-25
PL3697784T3 (pl) 2024-03-11
CO2020005200A2 (es) 2020-05-29
IL273943B2 (en) 2023-10-01
US20210169879A1 (en) 2021-06-10
US11564923B2 (en) 2023-01-31
ZA202002166B (en) 2021-05-26
DK3697784T5 (da) 2024-01-15
EP4265254A2 (en) 2023-10-25
TWI866258B (zh) 2024-12-11
AU2018350592B2 (en) 2022-12-22
TW201918483A (zh) 2019-05-16
EP3697784B9 (en) 2023-12-27
IL273943B1 (en) 2023-06-01
HRP20231315T1 (hr) 2024-02-16
US20230310433A1 (en) 2023-10-05
MA50391A (fr) 2021-04-21
FI3697784T3 (fi) 2023-10-31
HUE063998T2 (hu) 2024-02-28
AU2023201522B2 (en) 2024-11-28
MX2020003863A (es) 2020-08-13
EP3697784A1 (en) 2020-08-26
RU2020116376A3 (cg-RX-API-DMAC7.html) 2021-11-22
TW202411229A (zh) 2024-03-16
PH12020550230A1 (en) 2021-02-08
BR112020007541A2 (pt) 2020-09-24
JP7654031B2 (ja) 2025-03-31
JP2023113834A (ja) 2023-08-16
DK3697784T3 (da) 2023-10-30
US20260183288A1 (en) 2026-07-02
AU2018350592A1 (en) 2020-06-04
ES2967432T3 (es) 2024-04-30

Similar Documents

Publication Publication Date Title
JP7654031B2 (ja) 炎症性障害の治療のための新規化合物及びその医薬組成物
US20220340581A1 (en) Compounds and pharmaceutical compositions thereof for the treatment of diseases
US12264156B2 (en) Compounds and pharmaceutical compositions thereof for the treatment of diseases
US12606554B2 (en) Compounds and pharmaceutical compositions thereof for the treatment of diseases
WO2013117646A1 (en) Novel compound useful for the treatment of degenerative and inflammatory diseases
EP4017590A1 (en) Pyrazolo[4,3-c]pyridine derivatives and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2021032323A1 (en) Fused pyrimidine compounds and pharmaceutical compositions thereof for the treatment of fibrotic diseases
US20170057928A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
HK40101992A (en) Imidazo[4,5-b]pyridine compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
RU2785126C2 (ru) Новые соединения и их фармацевтические композиции для лечения воспалительных заболеваний
HK40035999B (en) Imidazo[4,5-b]pyridine compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
HK40035999A (en) Imidazo[4,5-b]pyridine compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
BR112020007541B1 (pt) Compostos, composições farmacêuticas e seus usos para o tratamento de distúrbios inflamatórios
BR122025019954A2 (pt) Compostos, composições farmacêuticas e seus usos para o tratamento de distúrbios inflamatórios